OpGen Data on New Rapid Gene Test and Antibiotic Susceptibility Prediction Algorithms Presented at the 2017 ASM/ESCMID Confer...
September 08 2017 - 7:30AM
OpGen, Inc. (NASDAQ:OPGN) today announced that the Company
presented study results on the company’s new rapid test in
development, the Acuitas® AMR Gene Panel u5.47, and the Acuitas
Lighthouse® Knowledgebase for prediction of antibiotic
susceptibility at the 2017 ASM/ESCMID Conference on Drug
Development to Meet the Challenge of Antimicrobial Resistance. The
poster presentation, titled “Predicting Antibiotic Resistance in
Gram-Negative Bacilli by Rapid Detection of Resistance Genes,” was
presented by Terry Walker, Ph.D., OpGen’s senior vice president of
research and development and the lead author on the study, on
September 7, 2017. The conference is being held September
6–8, 2017 at the Boston Park Plaza Hotel.
The poster includes data based on OpGen’s
analysis of the Merck Study for Monitoring Antimicrobial Resistance
Trends (SMART) clinical isolate archive by phenotypic antibiotic
susceptibility testing and a high-throughput PCR assay for 126
antibiotic resistance genes. Based on this analysis and additional
discovery work, OpGen is developing the Acuitas AMR Gene Panel
u5.47, a Research Use Only semi-quantitative PCR test that rapidly
detects antibiotic resistance genes. The semi-quantitative PCR test
detects 5 bacterial pathogens in clinical isolates and urine
specimens and detects 47 antimicrobial resistance genes. The poster
highlights in silico prediction results using the Acuitas
Lighthouse Knowledgebase to interpret test results from the Acuitas
AMR Gene Panel. Results of the study showed that the Acuitas
Lighthouse Knowledgebase predicted phenotypic antibiotic resistance
for 17 antibiotics based on 47 resistance genes, with agreement
ranging from 79% to 97% for E. coli, 78% to 90% for K. pneumoniae;
46% to 84% for P. aeruginosa; and 76% to 99% for P. mirabilis.
“Antimicrobial drug resistance is an urgent
global health concern, and there is a pressing need to provide
resistance information to healthcare providers more quickly,” said
Dr. Walker. “Our data show that the Acuitas AMR Gene Panel
accurately detects and quantitates key complicated urinary tract
infection pathogens. We are encouraged by the development
data for Acuitas Lighthouse Knowledgebase prediction algorithms
currently in development. The results from this study suggest the
AMR Gene Panel can potentially aid in the rapid detection of
resistance genes days ahead of antibiotic susceptibility testing,
which is the current standard guide for antibiotic therapy. An
early identification of antibiotic resistance genes may improve
antimicrobial stewardship and patient outcomes.”
About ASM/ESCMID
Antimicrobial drug resistance (AMR) is an urgent
global health problem. New antimicrobial drug development is
increasingly viewed as a priority by National and International
bodies. There are relatively few agents in developmental pipelines
and a paucity of identified microbiological targets that can be
exploited for drug development. Co-sponsored by the American
Society for Microbiology (ASM) and the European Society for
Clinical Microbiology and Infectious Diseases (ESCMID), this
multidisciplinary meeting will address the challenges,
opportunities and current requirements for antimicrobial drug
development for
AMR.
About OpGenOpGen,
Inc. is harnessing the power of informatics and genomic
analysis to provide complete solutions for patient, hospital and
network-wide infection prevention and treatment.
OpGen, Acuitas, Acuitas Lighthouse and
QuickFISH are registered trademarks of OpGen, Inc.
Forward-Looking Statements
This press release includes statements relating
to the company's products and services development efforts. These
statements and other statements regarding OpGen’s future plans and
goals constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to
differ materially from expectations. Factors that could cause our
results to differ materially from those described include, but are
not limited to, our ability to successfully, timely and
cost-effectively develop, seek and obtain regulatory clearance for
and commercialize our product and services offerings, the rate of
adoption of our products and services by hospitals and other
healthcare providers, the success of our commercialization efforts,
the effect on our business of existing and new regulatory
requirements, and other economic and competitive factors. For a
discussion of the most significant risks and uncertainties
associated with OpGen's business, please review our filings with
the Securities and Exchange Commission (SEC). You are cautioned not
to place undue reliance on these forward-looking statements, which
are based on our expectations as of the date of this press release
and speak only as of the date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
OpGen Contact:Michael FarmerSr. Director,
Marketing240-813-1284mfarmer@opgen.com InvestorRelations@opgen.com
Investor Contact:LHA Investor RelationsKim
Sutton Golodetz212-838-3777kgolodetz@lhai.com orBruce
Voss310-691-7100bvoss@lhai.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2023 to Sep 2024